1 / 1

DATABASE construction n=1,715 Median OS=40.0 months, age: 64+/-10 yrs

An online tool for the validation of survival-predicting biomarkers in non small-cell lung cancer using microarray data of 1,329 1,715 patients.

rhys
Download Presentation

DATABASE construction n=1,715 Median OS=40.0 months, age: 64+/-10 yrs

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. An online tool for the validation of survival-predicting biomarkers in non small-cell lung cancer using microarray data of 1,3291,715 patients Balázs Győrffy and András LánczkyResearch Laboratory for Pediatrics and Nephrology, Hungarian Academy of Sciences and Semmelweis University 1st Dept. of Pediatrics, Budapest, Hungary Background and Objective Results • optimized treatment for non-small cell lung cancer had lead to improved prognosis, but the overall survival is still very short • by identifying biomarkers related to survival we can further understand the molecular basis of the disease • OBJECTIVE: we present the development of an online available tool suitable for the real-time meta-analysis of published lung cancer microarray datasets to identify biomarkers related to survival • DATABASE construction • n=1,715 • Median OS=40.0 months, age: 64+/-10 yrs • Histology (adeno/squamous/large): 50% / 45% / 5% • Stage 1/2/3/4: 63% / 27% / 10% / 1% • META-ANALYSIS of biomarker candidates • Biomarker candidates identified in Pubmed n=22 • For each gene the exact conditions in which it was identified have been retrieved, and these have been used as filtering when selecting the patients for the survival analysis. • Of the 22, the best performing genes are: • n(1): number of patients in original study, n(2): number of patients in the KM-plotter, HR: hazard ratio, ADE: adenocarcinoma, NSCLC: all non-small-cell lung cancer patients • Selected KAPLAN-MEIER plots (table: *) Materials & Methods • DATABASE construction • Repositories: GEO, TCGA, ArrayExpress, caBIG • Platforms: Affymetrix HGU133A, plus2 & A 2.0 arrays • at least 30 patients with survival information • MAS5 normalization + quality control • SURVIVAL analysis • Kaplan-Meier plot • „survival” Bioconductor package • Cox univariate + multivariate analysis • ONLINE platform • Apache web server on Debian Linux • script developed in PHP • Open access at: www.kmplot.com/lung • META-analysis • Pubmed search of published biomarkers • Best cutoff selection: each percentile (of expression) between the lower and upper quartiles are computed and the best performing threshold is used as the final cutoff in the Cox regression analysis. Cyclin E1 CDK1 CADM1 Summary • we performed a meta-analysis of survival-associated genes • an integrated database and an online tool for future in silico validation of new candidates has been established Web addresses Online access: http://www.kmplot.com/lung Group homepage: http://gyer1-6.sote.hu/gyorffy Contact: gyorffy@kmplot.com Grant support: OTKA PD 83154, PREDICT 259303 (EU Health.2010.2.4.1.-8), KTIA EU_BONUS_12-1-2013-0003, Alexander von Humboldt-Foundation

More Related